Shattuck Labs Stock
Shattuck Labs, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Taylor H. Schreiber
- Employees
- 40
- Market cap
- $544 M
- IPO
- 09/10/2020
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing…
Shattuck Labs stock: price history
1D
-2.0%
1W
-9.2%
1M
-7.8%
6M
-28.0%
YTD
+48.5%
1Y
+201.1%
2Y
+273.8%
5Y
-72.0%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~1% stronger price swings than usual
Shattuck Labs stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Shattuck Labs is a U.S.-based biotechnology company in the clinical development phase headquartered in Austin, Texas. The company's primary objective is to develop innovative therapeutics for the treatment of cancer and autoimmune diseases. The current focus is on two drug candidates: SL-172154, which is in Phase 1 for the treatment of ovarian, fallopian tube, and peritoneal cancer, as well as SL-279252 for advanced solid tumors and lymphomas. The business model is currently entirely based on licensing fees, with the company still in an intensive research and development phase.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Shattuck Labs
Analyst assessment of Shattuck Labs
PRICE TARGET LOW
US$7.00
CONSENSUS
US$15.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$19.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 02/10/2026
Shattuck Labs stock metrics
P/E
-10.63
P/B
3.33
EV/EBITDA
-9.86
RETURN ON EQUITY
-7.2%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.9%
FLOAT SHARES
86,216,032
AVG. DAILY VOLUME (30D)
1,448,008
Insider transactions (SEC)
Shukla Abhinav A.
Shukla Abhinav A.
Shukla Abhinav A.
Pandite Arundathy N.
Shukla Abhinav A.
Institutional holders
Comparable stocks
Frequently asked questions about Shattuck Labs stock
What does Shattuck Labs do?
Shattuck Labs, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Taylor H. Schreiber, the company employs around 40 people.
The IPO was on 09/10/2020; the stock trades on NASDAQ under the ticker STTK.
What do analysts say about Shattuck Labs stock?
9 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$15.00, ranging from US$7.00 to US$19.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
When does Shattuck Labs report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Shattuck Labs pay a dividend?
No, Shattuck Labs currently does not pay a dividend.
Which stocks are comparable to Shattuck Labs?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Shattuck Labs stock analyzed?
Clicking "Analyze stock" lets five strategies assess Shattuck Labs against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.